C

CEL-SCI Corp
AMEX:CVM

Watchlist Manager
CEL-SCI Corp
AMEX:CVM
Watchlist
Price: 2.52 USD 6.33% Market Closed
Market Cap: 13m USD

CEL-SCI Corp
Investor Relations

CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. The company is headquartered in Vienna, Virginia. The firm is focused on activating the immune system to fight cancer and infectious diseases. The firm is engaged in research and developing of treatments for cancer and other diseases by using the immune system. Its lead investigational therapy Multikine (Leukocyte Interleukin, Injection) is in a pivotal phase III clinical trial. Its Multikine is an investigational immunotherapy under development for the potential treatment of certain head and neck cancers. The firm is using its Ligand Epitope Antigen Presentation System (LEAPS) technology to develop various new drug candidates, CEL-4000 and CEL-2000, as potential rheumatoid arthritis therapeutic treatments. Its product candidates using its LEAPS technology are CEL-2000, CEL-4000 and DerG-PG275(Cit). The Company’s Multikine is an immunotherapy product candidate comprised of a patented defined mixture of 14 human natural cytokines.

Show more
Loading
CVM
S&P 500
1Y 3Y 5Y 10Y 15Y 20Y

Earnings Calls

No Earnings Calls Available

Management

Mr. Geert R. Kersten Esq.
CEO, Treasurer & Director
No Bio Available
Ms. Patricia B. Prichep
Chief Financial and Operations Officer & Corporate Secretary
No Bio Available
Dr. Eyal Talor Ph.D.
Chief Scientific Officer
No Bio Available
Dr. Daniel H. Zimmerman Ph.D.
Senior Vice President of Research & Cellular Immunology
No Bio Available
Mr. John Cipriano
Senior Vice President of Regulatory Affairs
No Bio Available
Dr. Giovanni Selvaggi M.D.
Acting Chief Medical Officer
No Bio Available

Contacts

Address
VIRGINIA
Vienna
Suite 802, 8229 Boone Blvd .
Contacts
+17035069460
cel-sci.com
sparklesyt

See Also

Summary
CVM intrinsic value, competitors valuation, and company profile.
DCF Valuation
CVM stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CVM stock valuation using valuation multiples.
Wall Street Estimates
CVM price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CVM stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Back to Top
ALPHA SPREAD
Follow us
Join more than 265,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.